Dexamethasone sodium phosphate is under clinical development by EryDel and currently in the Phase I and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Dexamethasone sodium phosphate’s likelihood of approval (LoA) and phase transition for Ataxia-Telangiectasia (Louis-Bar Syndrome) took place on 10 Aug 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Dexamethasone sodium phosphate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Dexamethasone sodium phosphate overview

Dexamethasone sodium phosphate is under development for the treatment of ataxia telangiectasia, non ambulatory ataxia telangiectasia and Duchenne muscular dystrophy (DMD).. The drug candidate is administered as an intravenous infusion. It targets glucocorticoid receptor. The drug candidate is based on intra-erythrocytic technology by encapsulating dexamethasone sodium phosphate into human erythrocytes. It was also under development for the treatment of the Crohn's disease, cystic fibrosis, ulcerative colitis, chronic obstructive pulmonary disease, other chronic inflammatory diseases.

EryDel overview

EryDel operates as a biotechnology company specialized in the development of drugs and diagnostics delivered through human red blood cells using its proprietary drug delivery technology. The company offers Red Cell Loader (RCL), a proprietary non-invasive electromechanical device that automates the EryDex System (EDS) process enabling encapsulation of drugs with the use of disposable medical device (EryKit_01). Its pipeline product includes EryDex System (EDS) composed of device components including multi-use Red Cell Loader (RCL), the EryKit_01, and process solutions used to load dexamethasone sodium phosphate (DSP) into autologous erythrocytes, creating the EDS end product (EDS-EP) infused once per month to treat Ataxia Telangiectasia patients. EryDel is headquartered in Bresso, Italy.

Quick View Dexamethasone sodium phosphate LOA Data

Report Segments
  • Innovator
Drug Name
  • Dexamethasone sodium phosphate
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Central Nervous System
  • Gastrointestinal
  • Genetic Disorders
  • Immunology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.